Correction: Association of baseline inflammatory biomarkers with cancer mortality in the REGARDS cohort.

• Authors: Tomi Akinyemiju, Duke University; Justin X. Moore, Washington University in St. Louis; Daniel Tefera Dibaba, University of Tennessee; Maria Pisu, University of Alabama Birmingham; Michael Goodman, Emory University; Virginia J. Howard, University of Alabama Birmingham; Monkia Safford, Weill Cornell Medical College; Susan C. Gilchrist, University of Texas MD Anderson Cancer Center; Mary Cushman, University of Vermont; LeAnn Long, University of Alabama Birmingham; Suzanne E. Judd, University of Alabama Birmingham
• Journal Title: Oncotarget
• Volume: Volume 11, Number 7
• Publisher: Oncotarget | 2020-02-18, Pages 758-758
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.18632/oncotarget.27480
• Subjects: Health Sciences, Epidemiology; Health Sciences, Oncology
• Keywords: inflammatory biomarkers; racial disparities; cancer mortality; obesity

Abstract

This article has been corrected: The third author in the listing, along with a new affiliation, has been added as follows: Daniel Tefera Dibaba, Tennessee Clinical and Translational Science Institute, University of Tennessee Health Science Center, Memphis, TN, USA This study examines the association between inflammatory biomarkers and risk of cancer mortality by race. Data were obtained from 1,856 participants in the prospective REGARDS cohort who were cancer-free at baseline, and analyzed in relation to cancer mortality prospectively. Biomarkers were log-transformed and categorized into tertiles due to non-normal distributions, and Cox proportional hazard regression models were utilized to compute hazard ratios with 95% confidence intervals using robust sandwich methods. Individuals in the highest tertile of IL-6 had over a 12-fold increased risk of cancer mortality (HR: 12.97, 95% CI: 3.46–48.63); those in the highest tertile of IL-8 had over a 2-fold increased risk of cancer mortality (HR: 2.21, 95% CI: 0.86–5.71), while those in the highest tertile of IL-10 had over a 3-fold increased risk of cancer mortality (HR: 3.06, 95% CI: 1.35–6.89). In race-stratified analysis, each unit increase in IL-6 was associated with increased risk of cancer mortality among African-Americans (HR: 3.88, 95% CI: 1.17–12.88) and Whites (5.25, 95% CI: 1.24–22.31). If replicated in larger, racially diverse prospective cohorts, these results suggest that cancer patients may benefit from clinical or lifestyle approaches to regulate systemic inflammation as a cancer prevention strategy.